Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

This RCT of vulnerable older patients with ovarian cancer (n=120) found single-agent carboplatin was less feasible and active than a conventional carboplatin–paclitaxel regimen (6 cycles completed in 48% vs 60% of patients, respectively), leading to its premature termination.

Source:

JAMA Oncology